Sorin rejects analysts' forecast of divestment
This article was originally published in Clinica
Executive Summary
Sorin has dismissed speculation that it may divest its renal care business. Analysts at Morgan Stanley Dean Witter distributed a report on the Italian biomedical company last month which said: "Although [the renal care business] is profitable and generates cash, we believe, based on the company's stated strategy, that Sorin would entertain exiting the business if the right opportunity, for example an attractive cardiovascular surgery business, came along."